Camarda Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Camarda Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,037	Closed	-$1.57M	–	119
2025 Q4	$1.57M	Buy	+2,037	New	+$1.38M	0.6%	53
2024 Q4	–	Sell	-1,435	Closed	-$1.51M	–	107
2024 Q3	$1.51M	Sell	1,435 -21	-1%	-$23.4K	0.57%	55
2024 Q2	$1.53M	Buy	1,456 +372	+34%	+$361K	0.6%	53
2024 Q1	$1.04M	Buy	+1,084	New	+$1.03M	0.42%	57
2019 Q2	–	Sell	-5	Closed	-$2K	–	566
2019 Q1	$2K	Buy	+5	New	+$2.06K	﹤0.01%	375

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Camarda Financial Advisors's REGN Position: Q1 2026 in Review

Camarda Financial Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 2,037 shares — an estimated $1.57M sold.

Camarda Financial Advisors first reported a position in REGN in Q1 2019 and held it in 5 quarters. The position peaked at $1.57M in Q4 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Camarda Financial Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Camarda Financial Advisors sold 2,037 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.57M.
Camarda Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 5 quarters.
Camarda Financial Advisors's Regeneron Pharmaceuticals position peaked at $1.57M in Q4 2025.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Camarda Financial Advisors's 13F filing for Q1 2026, filed 14 May 2026.